More than 300 meds in development in USA for autoimmune diseases, says report
A new report from US trade group Pharmaceutical Research and Manufacturers of America (PhRMA) and the Lupus Foundation of America reveals that there are 311 medicines and vaccines being developed by US companies which are in clinical trials or pending review by the Food and Drug Administration for autoimmune diseases.
The report highlights both the progress made in increasing understanding of the immune system and what remains to be learned.
Currently, more than 80 autoimmune diseases have been identified, including psoriasis, lupus and celiac disease, and new scientific advances – led by pharma companies – continue to reveal details that are spurring the development of innovative approaches to treating them, such as how environmental elements can trigger the immune system to attack normal cells.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze